Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, autonomic balance in heart failure patients

Journal of Clinical Pharmacology

Volumn 41, Issue 1, 2001, Pages 97-106

  Graff, Donald W ^a   Williamson, Kristin M ^a   Pieper, John A ^a   Carson, Stanley W ^a   Adams, Kirkwood F ^b   Cascio, Wayne E ^b   Patterson, J Herbert ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; DEBRISOQUINE 4 HYDROXYLASE; FLUOXETINE; PLACEBO;

ADULT; AGED; AMBULATORY MONITORING; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; ELECTROCARDIOGRAPHY; ENANTIOMER; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AUTONOMIC NERVOUS SYSTEM; CARBAZOLES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FLUOXETINE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM;

EID: 0034749793     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122009746     Document Type: Article

References (39)

1. HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction-pharmacological approaches
2. Effects of beta-blocker therapy on mortality in patients with congestive heart failure: A systematic overview of randomised controlled trials
3. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
4. Clinical effects of β-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo controlled, randomized trials
5. The cardiac insufficiency bisoprolol study II (CIBIS II): A randomised trial
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
7. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound
8. In vitro identification of the human cytochrome p450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol
9. Dose proportional stereoselective kinetics of carvedilol in patients with CHF
10. Populations pharmacokinetics of R(+) and S(-) carvedilol in patients with congestive heart failure (CHF), NYHA class II-IV
11. Pharmacological characteristics of the stereoisomers of carvedilol
12. Nortriptyline in depressed patients with left ventricular impairment
13. Tricyclic antidepressants in depressed patients with cardiac conduction disease
14. Psychiatric aspects of cardiovascular disease
15. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes
16. Depression and 18 month prognosis after myocardial infarction
17. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use
18. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction
19. Frequency domain measures of heart period variability and mortality after myocardial infarction
20. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
21. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure
22. Effects of beta blockers (atenolol and metoprolol) on heart rate variability after acute myocardial infarction
23. Effects of bisoprolol on heart rate variability in heart failure
24. Long-term β-blocker thenrapy improves autonomic nervous regulation in advanced congestive heart failure: A longitudinal heart rate variability study
25. High-performance liquid chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its O-desmethyl metabolite in human plasma after chiral derivatization
26. Assay and disposition of carvedilol enantiomers in humans and monkeys: Evidence of stereoselective presystemic metabolism
27. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high performance liquid chromatography with application to their disposition in man
28. High-performance liquid chromatographic assay for imipramine desipramine, and their 2-hydroxylated metabolites
29. Determination of fluoxetine and norfluoxetine by high performance liquid chromatography
30. Stereoselective disposition of carvedilol is determined by CYP2D6
31. Serum flouxetine and norfluoxetine concentrations and antidepressant response
32. Fluoxetme treatment of depression
33. Fluoxetine: Relationships among doe, response, adverse events, and plasma concentrations in the treatment of depression
34. Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
35. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency
36. Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function
37. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart)
38. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol